Leveraging the extensive knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.

Sentinella Pharmaceuticals, Inc. manufactures pharmaceutical products. The company was Founded by Lorenzo Pellegriniis and is headquartered in Princeton, NJ.

Oragenics are a biopharmaceutical company focused primarily on oral probiotics products and novel antibiotics for humans and companion pets. Within oral health we are commercializing our patented probiotic blend, ProBiora3® specifically formulated for oral health both under our branded Evora line and in private label configurations. Currently we have sales or contracts to sell these products in over 15 countries around the world. Our recent partnership with Intrexon in the field of Lantibiotics, a largely overlooked class of extremely potent gram-positive antibiotics, will help us to develop our pharmaceutical product candidate, MU1140-S™ and additional antibiotics from the Lantibiotic class for therapeutic use. The focus on the probiotic area will be to grow sales through a variety of channels including internet sales and the professional channel (dentists and hygienists) as well as through private label and bulk sales of our patented ProBiora3 blend. We intend to look for opportunities to expand our health claims for these products through a range of clinical studies. We are also looking at novel and convenient new delivery systems for our probiotics, which we plan to commercialize in the near future. In 2011 we received the Frost and Sullivan Award for excellence in probiotics. This was a competitive award that placed us as a leader in the probiotic space.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Boehringer Ingelheim Corporate Center GmbH, part of C.H. Boehringer Sohn AG & Co. KG, is a company headquartered in Ingelheim am Rhein, Germany. The firm leases real estate properties. It was founded in 2016.

LanthioPep BV specializes in vivo stability of therapeutic and diagnostic imaging peptides. Its products include pancyte, lanthi apelin and galanin agonist. The company is headquartered in Groningen, the Netherlands.

Biosynexus, Inc. develops and markets pharmaceutical products. The company is headquartered in Rockville, MD.

Beiersdorf AG is engaged in the development, manufacture, and distribution of skin and personal care products. The firm operates through the Consumer and Tesa segments. The Consumer segment concentrates on the international skin and body care markets. The Tesa segment manufactures self-adhesive products and solutions for industry, craft businesses, and consumers. It offers its products and system solutions to industry, craft businesses, and consumers. Its brands include Eucerin, La Prairie, Labello, and Hansaplast. The company was founded by Paul C. Beiesdorf in 1882 and is headquartered in Hamburg, Germany.

BLIS Technologies Ltd. engages in the development of healthcare products based on strains of bacteria that produce bacteriocin activity. It operates in the following geographical areas: Asia Pacific, Europe Middle East and Africa (EMEA), and North America. The company was founded by John R. Tagg in 2000 and is headquartered in Dunedin, New Zealand.

Rhodia, Inc. manufactures chemicals and engineering plastics. Its products include surfactants, silicones, silica, paint ingredients, and agricultural chemicals. The company was founded in 1948 and is headquartered in Cranbury, NJ.

Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany.

ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. Its products include first defense for scours, California mastitis test kits, and purified nisin intramammary treatment for mastitis. The company was founded in 1982 and is headquartered in Portland, ME.

Vicuron Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products for the treatment of seriously ill patients. Its lead products are in Phase III clinical trials and include anidulafungin, a novel antifungal agent; and dalbavancin, a novel intravenous antibiotic for the treatment of serious Gram-positive infections. The company�s products also include ramoplanin, which is an oral nonabsorbable form of antibiotic that selectively inhibits Gram-positive bacteria, and various types of vancomycin-resistant enterococci and Clostridia. In addition, it provides VIC-Acne, a topical antibiotic cream that is in Phase I clinical trail. Vicuron Pharmaceuticals has research collaboration agreements with Novartis Pharma AG to develop deformylase inhibitors as new antibacterial agents and to provide target-based screens; and Pfizer, Inc. to discover second and third generation oxazolidinones. The company was incorporated as Versicor, Inc. in 1995 and changed its name to Vicuron Pharmaceuticals, Inc. in 2003. Vicuron Pharmaceuticals is headquartered in King of Prussia, Pennsylvania. Vicuron Pharmaceuticals Inc. is a former subsidiary of Pfizer Inc.

Naicons is a biotechnology company devoted to discovering and developing novel bioactive compounds. Their own programs aim at combating and preventing a broad range of infectious diseases. By leveraging their technology platform and their expertise, Naicons supports many organizations

PBL develops innovative technologies from public and private sources worldwide - turning ideas into patented, scientifically validated and licensable technologies. PBL invests in building intellectual property protection, and develops technologies through proof-of-concept and prototype stage and licenses onwards to a wide variety of industry sectors. Our interests cover AgBiotech, Food / Nutrition, Microbiology, Biotechnology and related Life Science industries. We market our technologies internationally and have regular contact with a very wide range of industrial customers, licensees and development partners.

Allvivo is a biomedical company committed to the development of improved antimicrobial technologies to reduce medical device and wound related infections. With facilities in Lake Forest, California, Allvivo collaborates with licensees and marketing partners to deliver safe and effective treatment options that simplify infection control, improve patient outcomes, and improve healthcare economics.

Haarmann & Reimer Corp is a German company located in Holzminden with a presence in the United States that manufactures flavours and fragrances. EQT III Fund acquired Haarmann & Reimer Corp from Bayer AG on October 01, 2002 for $1,676.85 million.

DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases. It is at the intersection of two highly active sectors: dermatology and the microbiome. They harness naturally occurring microbes on the human skin that have evolved over hundreds of thousands of years to compete with pathogenic microbes (fungi, bacteria, viruses, etc.). The company was founded in 2017 and is headquartered in Boston, Massachusetts with a satellite office in Emeryville, California.

Boehringer Ingelheim Animal Health USA, Inc. manufactures biological vaccines for animals. The firm specializes in pharmaceuticals for cattle, equine, pet, and swine. The company was founded by Albrecht Boehringer in 1885 and is headquartered in Duluth, GA.